BioLineRx Ltd. (BLRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Quarterly

0 2M 4M 6M Q2 '23: 0 Q2 '24: 5.4M Q2 '25: 304K Q2 '23 Q2 '24 Q2 '25

Gross Profit Quarterly

0 2M 4M 6M Q2 '23: 0 Q2 '24: 4.5M Q2 '25: 232K Q2 '23 Q2 '24 Q2 '25

Operating Income Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q2 '17: -5.2M Q2 '18: -5.7M Q2 '19: -6.5M Q2 '20: -5.6M Q2 '21: -6.5M Q2 '22: -7.6M Q2 '23: -9.9M Q2 '24: -5.8M Q2 '25: -2.3M Q2 '17 Q2 '19 Q2 '21 Q2 '23 Q2 '25

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q2 '17: -4.9M Q2 '18: -4.8M Q2 '19: -5.5M Q2 '20: -6.8M Q2 '21: -6.8M Q2 '22: -7.4M Q2 '23: -18.5M Q2 '24: 484K Q2 '25: -3.9M Q2 '17 Q2 '19 Q2 '21 Q2 '23 Q2 '25

Cost of Revenue Quarterly

0 350K 700K 1.1M Q2 '23: 0 Q2 '24: 897K Q2 '25: 72K Q2 '23 Q2 '24 Q2 '25

Operating Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 900M 1.8B 2.7B Q2 '17: 94.5M Q2 '18: 106.6M Q2 '19: 145.5M Q2 '20: 220.3M Q2 '21: 669.1M Q2 '22: 715.4M Q2 '23: 923M Q2 '24: 1.2B Q2 '25: 2.4B Q2 '17 Q2 '19 Q2 '21 Q2 '23 Q2 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.